Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4064912 in Healthy Participants and Participants With Overweight or Obesity

NCT07152002 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07152002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07152002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4064912 in Healthy Participants and Participants With Overweight or Obesity
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
August 28, 2025
Completion date
August 26, 2026
Enrollment
77 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, overweight or obesity